NCT07371910 2026-01-28
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07314203 2026-01-02
SOP-XH-IRB
Fujian Medical University
Phase 3 Not yet recruiting
NCT06255392 2025-08-15
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05613478 2024-12-31
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT06438627 2024-07-16
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT06188455 2024-01-03
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
The First Affiliated Hospital of Xiamen University
Phase 3 Not yet recruiting
NCT05889871 2023-06-05
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Fudan University
Phase 3 Not yet recruiting
NCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT03889626 2019-03-26
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Fudan University
Phase 3 Unknown
NCT03651219 2018-08-29
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
Beijing Chest Hospital
Phase 3 Unknown
NCT03598348 2018-07-26
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 3 Unknown
NCT03355612 2017-11-28
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03100955 2017-04-04
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
Qingdao University
Phase 3 Unknown
NCT02537171 2016-08-02
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 3 Unknown
NCT02824458 2016-07-07
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Sun Yat-sen University
Phase 3 Unknown
NCT01287962 2013-12-09
Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Unknown